Equities Analysts Set Expectations for XBIO Q2 Earnings

Xenetic Biosciences Inc (NASDAQ:XBIO) – Analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Xenetic Biosciences in a research report issued on Wednesday, May 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.64) for the quarter, up from their prior estimate of ($0.79). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.68) EPS, FY2025 earnings at ($2.56) EPS, FY2026 earnings at ($4.46) EPS, FY2027 earnings at ($0.43) EPS and FY2028 earnings at ($0.35) EPS.

Xenetic Biosciences Trading Down 3.3%

Shares of NASDAQ:XBIO opened at $2.91 on Friday. The stock has a fifty day simple moving average of $2.86 and a two-hundred day simple moving average of $3.66. The stock has a market capitalization of $4.49 million, a price-to-earnings ratio of -1.09 and a beta of 2.31. Xenetic Biosciences has a 12-month low of $2.20 and a 12-month high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.13. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The company had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.52 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Xenetic Biosciences stock. LGT Group Foundation purchased a new position in Xenetic Biosciences Inc (NASDAQ:XBIO) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned about 0.71% of Xenetic Biosciences at the end of the most recent reporting period. 15.12% of the stock is owned by institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.